Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 50


Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.

Ding X, Cao H, Chen X, Jin H, Liu Z, Wang G, Cai L, Li D, Niu C, Tian H, Yang L, Zhao Y, Li W, Cui J.

J Transl Med. 2015 May 13;13:158. doi: 10.1186/s12967-015-0514-0.


Adoptive T cell immunotherapy for cancer.

Perica K, Varela JC, Oelke M, Schneck J.

Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004. doi: 10.5041/RMMJ.10179. eCollection 2015 Jan. Review.


Is there a subgroup of long-term evolution among patients with advanced lung cancer?: hints from the analysis of survival curves from cancer registry data.

Sanchez L, Lorenzo-Luaces P, Viada C, Galan Y, Ballesteros J, Crombet T, Lage A.

BMC Cancer. 2014 Dec 11;14:933. doi: 10.1186/1471-2407-14-933.


Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.

Singh BH, Gulley JL.

Ther Adv Vaccines. 2014 Sep;2(5):137-48. doi: 10.1177/2051013614539478. Review.


Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.

Singh BH, Gulley JL.

Asian J Androl. 2014 May-Jun;16(3):364-71. doi: 10.4103/1008-682X.122585. Review.


Novel antibody-based proteins for cancer immunotherapy.

Fuenmayor J, Montaño RF.

Cancers (Basel). 2011 Aug 19;3(3):3370-93. doi: 10.3390/cancers3033370.


Update on vaccine development for renal cell cancer.

Chi N, Maranchie JK, Appleman LJ, Storkus WJ.

Open Access J Urol. 2010 Aug 4;2:125-41. Review.



Chi N, Maranchie JK, Appleman LJ, Storkus WJ.

Open Access J Urol. 2010 Aug;2010(2):125-141.


High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro.

Lin AY, Lunsford J, Bear AS, Young JK, Eckels P, Luo L, Foster AE, Drezek RA.

Nanoscale Res Lett. 2013 Feb 12;8(1):72. doi: 10.1186/1556-276X-8-72.


CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.

Boissonnas A, Licata F, Poupel L, Jacquelin S, Fetler L, Krumeich S, Théry C, Amigorena S, Combadière C.

Neoplasia. 2013 Jan;15(1):85-94.


Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.

Gómez RE, Ardigo ML.

Front Oncol. 2012 Oct 29;2:147. doi: 10.3389/fonc.2012.00147. eCollection 2012.


Therapeutic vaccines: the ultimate personalized therapy?

Gulley JL.

Hum Vaccin Immunother. 2013 Jan;9(1):219-21. doi: 10.4161/hv.22106. Epub 2012 Sep 20.


Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.

Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI.

Cancer Res. 2012 Nov 1;72(21):5483-93. doi: 10.1158/0008-5472.CAN-12-2236. Epub 2012 Aug 31.


Cancer immunotherapy products: regulatory aspects in the European Union.

Camarero J, Ruiz S.

Hum Vaccin Immunother. 2012 Sep;8(9):1354-9. doi: 10.4161/hv.21142. Epub 2012 Aug 6.


Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.

Semin Oncol. 2012 Jun;39(3):296-304. doi: 10.1053/j.seminoncol.2012.02.010. Review.


Immunotherapy of cancer in 2012.

Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S.

CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. Review.


Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.

Amato RJ, Stepankiw M.

Clin Med Insights Oncol. 2012;6:67-73. doi: 10.4137/CMO.S7654. Epub 2012 Jan 5.


Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.

Bilusic M, Gulley JL.

Cancer Immunol Immunother. 2012 Jan;61(1):109-17. doi: 10.1007/s00262-011-1141-0. Epub 2011 Nov 26. Review.


A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.

Clin Cancer Res. 2011 Nov 15;17(22):7164-73. doi: 10.1158/1078-0432.CCR-11-0649. Epub 2011 Nov 8.


Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Bilusic M, Heery C, Madan RA.

Vaccine. 2011 Sep 2;29(38):6485-97. doi: 10.1016/j.vaccine.2011.06.088. Epub 2011 Jul 7. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk